Dr. Saumya Das, MD, PhD, is a Professor of Medicine at Harvard Medical School, a faculty member of the Cardiac Arrhythmia Service, and the co-Director of the Inherited Arrhythmia Program at Massachusetts General Hospital (MGH).

Dr. Das completed his residency in internal medicine at MGH, followed by fellowship training in cardiovascular disease and clinical cardiac electrophysiology at MGH. He then undertook a research post-doctoral fellowship with Dr. Rosenzweig, studying signaling pathways in cardiac electrical remodeling, before starting his own laboratory at Beth Israel Deaconess Medical Center in 2011. He was recruited to MGH in 2016. His research focuses on signaling pathways in electrical and structural remodeling in models of heart failure and cardiometabolic disease, with particular emphasis on extracellular vesicles and their cargo RNAs as biomarkers and mediators of intercellular signaling.

Dr. Das has served as the lead Principal Investigator (PI) of several National Center for Advanced Translational (NCAT) grants aimed at discovering and validating RNA biomarkers of heart remodeling in heart failure. As part of the NIH Extracellular RNA Communication Consortium, he co-chaired the steering committee. He was inducted into the American Society of Clinical Investigation in 2020 and received the NIH EIA award (R35).

Research conducted in Dr. Das’s laboratory has led to several patents. He is a co-founder of Thryv Therapeutics and Switch Therapeutics, based on discoveries made in his lab.

Dr. Das graduated summa cum laude in Biology from Harvard College, earned his MD from Harvard Medical School, and his PhD from the Harvard Graduate School of Arts and Sciences.